Modern Chemotherapy Management of Recurrent Ovarian Cancer: A Multicentre Study

Chan, Stephen Y.; Griffin, MJ; Stewart, Jocelyn M.; Gregory, Kate; Hughes, Amanda; Awwad, S.; Allerton, R.; Pledge, S.; Thomas, H Lucy; Percival, Fran

doi:10.1016/j.clon.2006.10.002

Cited by 6 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients present with advanced stage disease and the primary treatment modality is surgical cytoreduction followed by platinum/taxane-based chemotherapy. Relapsed disease is classified by its likely response to further treatment with platinum-based chemotherapy, being either platinum sensitive or platinum resistant (2). However, the majority of patients eventually develop progressive platinum resistance.…”

Section: Introductionmentioning

confidence: 99%

Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume

Rockall

Avril

Lam

et al. 2014

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Repeatability of baseline FDG-PET/CT measurements has not been tested in ovarian cancer. This dual-center, prospective study assessed variation in tumor 2[18F]fluoro-2-deoxy-D-glucose (FDG) uptake, tumor diameter, and tumor volume from sequential FDG-PET/CT and contrast-enhanced computed tomography (CECT) in patients with recurrent platinum-sensitive ovarian cancer.Experimental Design: Patients underwent two pretreatment baseline FDG-PET/CT (n ¼ 21) and CECT (n ¼ 20) at two clinical sites with different PET/CT instruments. Patients were included if they had at least one target lesion in the abdomen with a standardized uptake value (SUV) maximum (SUVmax) of !2.5 and a long axis diameter of !15 mm. Two independent reading methods were used to evaluate repeatability of tumor diameter and SUV uptake: on site and at an imaging clinical research organization (CRO). Tumor volume reads were only performed by CRO. In each reading set, target lesions were independently measured on sequential imaging.Results: Median time between FDG-PET/CT was two days (range 1-7). For site reads, concordance correlation coefficients (CCC) for SUVmean, SUVmax, and tumor diameter were 0.95, 0.94, and 0.99, respectively. Repeatability coefficients were 16.3%, 17.3%, and 8.8% for SUVmean, SUVmax, and tumor diameter, respectively. Similar results were observed for CRO reads. Tumor volume CCC was 0.99 with a repeatability coefficient of 28.1%.Conclusions: There was excellent test-retest repeatability for FDG-PET/CT quantitative measurements across two sites and two independent reading methods. Cutoff values for determining change in SUVmean, SUVmax, and tumor volume establish limits to determine metabolic and/or volumetric response to treatment in platinum-sensitive relapsed ovarian cancer. Clin Cancer Res; 20(10); 2751-60. Ó2014 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume

Rockall

Avril

Lam

et al. 2014

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Patients with recurrent ovarian cancer now have improved survival due to more effective anticancer drugs (8,9). In our institution, about half of the patients with recurrence of advanced ovarian cancer have received chemotherapy beyond third-line treatment for recurrence since 2006 ( Table 1).…”

Section: Discussionmentioning

confidence: 99%

Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy

Shimada

Saito

Shimokawa³

et al. 2017

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: The prognosis of ovarian cancer has improved because of platinum-and taxanecontaining chemotherapy. We investigated the 5-year disease-specific overall survival and prognostic factors of patients with advanced ovarian cancer to elucidate the change in clinical course of ovarian cancer with the advance of chemotherapy for patients who developed relapse in the era before the addition of molecular targeting therapy. Methods: We reviewed the clinical course of 134 patients with advanced ovarian cancer (FIGO Stage III and IV) treated in the past 11 years (1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010). We classified the patients into two groups: those who had been diagnosed with ovarian cancer from 1999 to 2005 (Group A) and those who had been diagnosed from 2006 to 2010 (Group B). We compared the 5-year diseasespecific overall survival and median survival rates between these two groups. We also investigated the prognostic factors of 104 patients who developed relapse. Results: The 5-year disease-specific overall survival rate was significantly higher in Group B than A (67.0% vs. 38.6%; P = 0.032). Chemotherapy containing pegylated liposomal doxorubicin hydrochloride, non-clear cell adenocarcinoma and intestinal resection were independent prognostic factors. Conclusions: The induction of new chemotherapeutic drugs and the increased variation of secondor third-line chemotherapy affected the improvement in overall survival of patients with advanced epithelial ovarian cancer.

show abstract

Aspidin BB, a phloroglucinol derivative, induces cell cycle arrest and apoptosis in human ovarian HO-8910 cells

Sun

et al. 2013

Chemico-Biological Interactions

View full text Add to dashboard Cite

Modern Chemotherapy Management of Recurrent Ovarian Cancer: A Multicentre Study

Cited by 6 publications

References 5 publications

Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume

Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume

Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy

Aspidin BB, a phloroglucinol derivative, induces cell cycle arrest and apoptosis in human ovarian HO-8910 cells

Contact Info

Product

Resources

About